Relations between epidermal growth factor receptor and oestrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients in Kuwait

Nasralla, Magdy; Paszko, Z; Omar, Y.T.; Ali, Masarrat; Jazzaf, H; Padzik, H

doi:10.1016/0959-8049(93)90580-9

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We must also not forget the psychological and psychiatric morbidity, not just for the patient but family and generation as well. [1,6,9,11,[13][14]…”

Section: Discussionmentioning

confidence: 99%

“…[6] The challenges in these countries are lack of awareness, social barriers, access to imaging, stage at presentation, adequacy of management, availability of latest management options, low priority for health, healthcare standards, healthcare infrastructure, and poor follow-up data. [6][7][8][9][10][11] Cancer is a known disease of aging. With the exception of pediatric malignancies, the risk of cancer increases with age.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Age at diagnosis of female breast cancer in Oman: Issues and implications

Mehdi

Monem

Bahrani

et al. 2014

South Asian J Cancer

View full text Add to dashboard Cite

Introduction:Female breast cancer (BC) is the most frequent malignancy diagnosed globally, about 23% of the diagnosed cancers. BC incidence varies geographically, highest in Western Europe and lowest in Africa. BC in females is strongly correlated to age, the highest incidence rate amongst older women reinforcing the importance of hormonal status. BC in young females has an aggressive phenotype. There is a shared observation amongst practicing oncologists that BC in Middle East and the developing world presents at an earlier age.Aim and Objective:The aims of this study are to evaluate the age at presentation of female BC in Oman, and to compare our data with international and regional published data. It discusses the impact of young age Breast Cancer.Materials and Methods:All diagnosed female BC cases registered from 1996-2010 all over the country, were retrieved from the National Cancer Registry, Ministry of Health. BC cases were analyzed with respect to age at presentation. The data were compared with regional and international data.Results:A total of 14,109 cancer cases were recorded during the period of study. BC was the leading malignancy as 1,294 cases (9.1%). Female BC patients were 1,230; denoting 19.2% of all female cancers. 53.5% of female BC presented below 50 years of age. Male BC constituted 5% of total, with 67% of male BC occurring over 50 years of age. Compared with data from Oman, the highest rates in UK and other Western countries are above 50 years of age. These rates are four to 10 times higher than local in different age groups. Interestingly, these rates increase with increasing age in UK from 40-45 to up to 85+, keep on increasing and go up to four times higher with higher age. This phenomenon, of increasing incidence rates with age, is not observed in our local population.Discussion:BC is significantly correlated to age as reported from Western population. BC is reported at a younger age from developing and Arab World, which need to be further studied and validated. This phenomenon of BC in younger age may have significant implications and effects ranging from screening, diagnosis, management, prognosis, and cost of treatment.Conclusion:The impact on young women diagnosed with BC is enormous, ranging from psychosocial to healthcare services and economics. There is a need to study it further in depth in developing World.

show abstract

“…We must also not forget the psychological and psychiatric morbidity, not just for the patient but family and generation as well. [1,6,9,11,[13][14]…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Age at diagnosis of female breast cancer in Oman: Issues and implications

Mehdi

Monem

Bahrani

et al. 2014

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer

Ciaparrone¹,

Terribile

Curigliano³

et al. 1998

The Breast Journal

View full text Add to dashboard Cite

An immunohistochemical comparative analysis of P-170 glycoprotein and p53 was performed in 37 breast cancer patients who underwent curative resection without preoperative chemotherapy. The antibodies utilized were C-219 and JSB-1 for P-gp and DO-7 for p53. Positive cytoplasmic and membrance positivity for P-gp was found in 22 (59.45%) of the 37 tumor specimens. In comparing tissue immunoreactivity by the specific antibodies, 15 (40.54%) samples showed immunostaining for C-219, 12 (32.43%) for JSB-1, and 5 (23%) for both. P-gp expression was not statistically related with the clinicopathological variables analyzed, that is, age, TNM stage, histologic type, lymph node involvement, tumor diameter, and hormone receptor status. p53 overexpression was observed in 22 (59.45%) of the 37 tumor samples analyzed. There was a significant correlation between p53 overexpression and P-gp positive immunostaining (p = .007). p53 was also significantly correlated with TNM stage (p < .05) and lymph node involvement (p < .02). Our results demonstrated that the three distinct patterns of reactivity with the two antibodies result from the combined expression of each of the three P-gp isoforms. An immunohistochemical analysis with different antibodies may be used to determine and correlate the expression pattern of P-gp isoforms with response to chemotherapy.

show abstract

Immunohistochemical detection of EGFR, p185^erbB-2, Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women

Talley

Chhieng

Bell

et al. 2008

Biotechnic & Histochemistry

View full text Add to dashboard Cite

Young pre-menopausal women with breast carcinomas have an overall worse prognosis than older, post-menopausal women. Because histologic grade is a major predictor of tumor behavior and correlates with biomarker expression, we assessed the immunohistochemical expression of epidermal growth factor receptor (EGFR), p185(erbB-2) and Bcl-2, and nuclear accumulation of p53 in breast carcinomas in pre- and post-menopausal women with equivalent histologic grades. This allowed identification of differences in biomarker expression and prognostic significance in pre- and post-menopausal women independent of histologic grade. We investigated 100 infiltrating ductal carcinomas (IDC) in pre-menopausal women, ages 45 years and younger, and 100 IDC in post-menopausal women, ages 65 years and older. The IDC were selected so that the proportions of high and low/moderate grade carcinomas were equal in the pre- and post-menopausal groups. Prognostic utility of biomarker expression in pre- and post-menopausal groups was determined by product limit and multivariate analysis of survival. There were statistically significant differences in cytoplasmic expression of EGFR and Bcl-2 and nuclear accumulation of p53, but not in the expression of p185(erbB-2), in carcinomas of high vs. low histologic grade. There was no difference in the expression of EGFR, p185(erbB-2) or Bcl-2, or in nuclear accumulation of p53 in these IDC from pre- vs. post-menopausal women. Bcl-2 and the nuclear accumulation of p53 were of prognostic significance in our overall study population; however, when assessing pre- and post-menopausal women separately, Bcl-2 and p53 were of prognostic significance only in pre-menopausal, but not post-menopausal women. In summary expression of EGFR and Bcl-2 and nuclear accumulation of p53 were significantly associated with histologic grade, but not with menopausal status. In addition, there were differences in the prognostic effectiveness of these biomarkers in pre- vs. post-menopausal women.

show abstract

Relations between epidermal growth factor receptor and oestrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients in Kuwait

Cited by 4 publications

References 11 publications

Age at diagnosis of female breast cancer in Oman: Issues and implications

Age at diagnosis of female breast cancer in Oman: Issues and implications

P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer

Immunohistochemical detection of EGFR, p185^erbB-2, Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women

Contact Info

Product

Resources

About

Relations between epidermal growth factor receptor and oestrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients in Kuwait

Cited by 4 publications

References 11 publications

Age at diagnosis of female breast cancer in Oman: Issues and implications

Age at diagnosis of female breast cancer in Oman: Issues and implications

P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer

Immunohistochemical detection of EGFR, p185erbB-2, Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women

Contact Info

Product

Resources

About

Immunohistochemical detection of EGFR, p185^erbB-2, Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women